ArticleAnnals of medicine and surgery (2012)2026
Nanorobots crossing the blood-brain barrier for targeted chemotherapy: the next frontier.
Article in Annals of medicine and surgery (2012), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The impermeability of the blood-brain barrier (BBB) remains one of the greatest challenges in neuro-oncology, limiting the effectiveness of chemotherapeutic delivery to malignant brain tumors. Programmable nanorobots, nanoscale devices with autonomous or guided motion have emerged as a transformative technology capable of actively crossing the BBB and releasing cytotoxic drugs directly at tumor sites. By integrating biomimetic coatings, enzymatic propulsion, and PH-responsive targeting, these systems achieve selective tumor accumulation while minimizing systemic toxicity. Preclinical studies from China, the United States, and Europe demonstrate significant advances in nanorobot-assisted chemotherapy, heralding a paradigm shift in glioblastoma management. Despite promising results, clinical translation requires careful attention to safety, biocompatibility, and regulatory oversight. This letter outlines current progress, key technical strategies, and future directions in nanorobotic chemotherapy. The approach holds profound implications for precision medicine and offers renewed hope for patients with intractable brain malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.